Overview
For patients with multiple myeloma, lymphoma, or other blood cancers requiring the most advanced therapies — CAR-T cell therapy, stem cell transplantation, and cutting-edge novel agents — the experience and international training of the treating physician are critical. Shanghai's Oriental Hospital is home to one of the city's most competitive hematology departments, led by a specialist who trained at one of the world's top myeloma centers in the United States and has built a program that ranks among Shanghai's finest for blood cancer treatment.
China Medical Concierge Shanghai (CMCS) connects international patients with Shanghai's top hematology specialists, providing end-to-end support from remote consultation through to post-treatment follow-up.
Understanding Blood Cancers: Myeloma, Lymphoma & Related Conditions
Multiple Myeloma
Multiple myeloma is a cancer of plasma cells in the bone marrow, characterized by bone destruction, anaemia, renal impairment, and hypercalcaemia. While incurable with standard therapy, outcomes have been transformed by novel agents — proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies, bispecific antibodies, and CAR-T therapy — with long-term disease control increasingly achievable.
Lymphoma
Lymphoma encompasses over 80 subtypes of lymphocyte-derived cancers, ranging from indolent to highly aggressive. Treatment varies dramatically by subtype and includes chemoimmunotherapy, targeted therapy, CAR-T, and stem cell transplantation for relapsed/refractory disease.
Common Symptoms
Myeloma:
- Bone pain, pathological fractures, back pain
- Fatigue and anaemia
- Recurrent infections
- Renal impairment and hypercalcaemia
Lymphoma:
- Painless lymph node swelling
- Fever, night sweats, unexplained weight loss
- Fatigue and itching
Treatment: CAR-T, Novel Agents & Stem Cell Transplantation
CAR-T Cell Therapy
CAR-T (chimeric antigen receptor T-cell) therapy represents one of the most significant advances in blood cancer treatment of the past decade. By engineering a patient's own T-cells to recognize and destroy cancer cells, CAR-T therapy achieves remarkable response rates in patients who have exhausted conventional options:
- CD19-targeted CAR-T for B-cell lymphoma — complete response rates of 40–54% in relapsed/refractory large B-cell lymphoma
- BCMA-targeted CAR-T for multiple myeloma — response rates of 70–98% in heavily pre-treated relapsed/refractory myeloma
- CD19-targeted CAR-T for ALL — complete response rates of 70–90% in relapsed/refractory B-ALL
Novel Agent Therapy for Myeloma
- Induction — Dara-VRd (daratumumab, bortezomib, lenalidomide, dexamethasone) quadruplet for newly diagnosed transplant-eligible patients
- Anti-CD38 antibodies — daratumumab, isatuximab for relapsed/refractory disease
- Bispecific antibodies — teclistamab, elranatamab (BCMA×CD3); talquetamab (GPRC5D×CD3)
- Antibody-drug conjugates — belantamab mafodotin
- Selinexor — for heavily pre-treated disease
Autologous Stem Cell Transplantation (ASCT)
For eligible patients with newly diagnosed myeloma or relapsed/refractory lymphoma achieving a response to salvage therapy, high-dose chemotherapy followed by ASCT remains a cornerstone of treatment — offering the best chance of deep, durable remission. The expertise of the transplant team in patient selection, conditioning regimen optimization, and post-transplant management is critical to achieving optimal outcomes.
Allogeneic Stem Cell Transplantation
For selected high-risk myeloma patients or those with relapsed disease after ASCT, allogeneic HSCT — using a matched or haploidentical donor — offers the potential for a graft-versus-myeloma effect and long-term disease control.
Why Choose Oriental Hospital for Blood Cancer Treatment?
- One of Shanghai's most competitive hematology departments — ranked among the top hematology programs in Shanghai
- International training at a top US myeloma center — Prof. Shi brings world-class expertise developed at one of America's premier myeloma programs
- Full CAR-T capability — CD19-targeted and BCMA-targeted CAR-T therapy for lymphoma and myeloma
- Comprehensive transplantation program — autologous and allogeneic HSCT
- Access to all novel agents — bispecific antibodies, ADCs, and clinical trials
- Cost-effective world-class care — significantly lower cost than equivalent treatment in the US, UK, or Singapore
Featured Specialist: Prof. Shi Jumei — Oriental Hospital, Tongji University
Prof. Shi Jumei (施菊妹) is a Professor of Hematology, Vice President of Oriental Hospital, and Director of the Department of Hematology at Oriental Hospital, Tongji University — one of Shanghai's major academic medical centers. She is one of the few Chinese hematologists to have trained and worked for multiple years at a top-tier myeloma center in the United States — an experience that has shaped her clinical approach and brought international best practices directly to her Shanghai program.
International Training: Top US Myeloma Center
Prof. Shi's extended training and clinical experience at one of America's premier myeloma centers gives her a depth of expertise in myeloma management — particularly in novel agent therapy, CAR-T, and transplantation — that is rare among Chinese hematologists. This international perspective, combined with her leadership of one of Shanghai's most competitive hematology departments, makes her an outstanding choice for patients seeking world-class myeloma care in Shanghai.
Shanghai's Most Competitive Hematology Department
Under Prof. Shi's leadership, the Oriental Hospital Department of Hematology has established itself as one of Shanghai's most competitive hematology programs — with particular strength in myeloma, lymphoma, CAR-T therapy, and stem cell transplantation. The department's competitive ranking reflects both the quality of its clinical outcomes and the breadth of its treatment capabilities.
Clinical Expertise
- Multiple myeloma — newly diagnosed and relapsed/refractory disease; novel agents, CAR-T, and transplantation
- Lymphoma — comprehensive management including CAR-T for relapsed/refractory B-cell lymphoma
- CAR-T cell therapy — CD19-targeted (lymphoma/ALL) and BCMA-targeted (myeloma)
- Autologous stem cell transplantation — for myeloma and lymphoma
- Allogeneic stem cell transplantation — for high-risk and relapsed disease
- Novel agent therapy — bispecific antibodies, ADCs, proteasome inhibitors, IMiDs, anti-CD38 antibodies
For international patients, Prof. Shi's team offers remote pre-consultation review of bone marrow biopsy, M-protein studies, molecular profiling, and prior treatment records, enabling a precise treatment recommendation to be developed before arrival in Shanghai.
How CMCS Supports Your Journey
CMCS is not a hospital — we are your dedicated medical concierge, providing a trusted bridge between international patients and Shanghai's finest cancer specialists.
Our services include:
- ✅ Direct appointment coordination with Prof. Shi Jumei and the Oriental Hospital hematology team
- ✅ Bone marrow biopsy, M-protein studies, molecular profiling, and prior treatment record translation and pre-consultation review
- ✅ CAR-T therapy and clinical trial eligibility assessment
- ✅ Second opinion facilitation
- ✅ Hospital admission and treatment scheduling support
- ✅ Accommodation and logistics coordination in Shanghai
- ✅ Post-treatment follow-up and remote check-in support
Contact CMCS
If you or a loved one has been diagnosed with multiple myeloma, lymphoma, or another blood cancer and would like to explore treatment options in Shanghai, our team is ready to help.
📧 Email: contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 Website: www.medicalsh.com
CMCS — China Medical Concierge Shanghai. Connecting international patients with Shanghai's finest specialists.
0件のコメント